miR-29a在骨肉瘤中的表达及预后研究

Study on the expression of miR-29a in osteosarcoma and prognosis

目的研究miR-29a在骨肉瘤及配对癌旁中的表达情况,及与其临床资料的关系。方法选取2012年3月至2014年12月南阳市第二人民医院收治的32例骨肉瘤患者,采用荧光实时定量PCR(real-time reverse transcription,q RT-PCR)的方法检测癌及癌旁组织中miR-29a的表达情况,分析其与患者临床资料及预后的关系。结果癌组织中miR-29a的平均表达量比癌旁组织下调。miR-29a与骨肉瘤病理分级呈负性相关关系,和临床分期呈正性相关关系(P均<0.05)。Cox回归多因素分析发现临床分期和miR-29a为患者独立的预后因子。结论 miR-29a在骨肉瘤的发生及进展中发挥关键的调节作用,有作为骨肉瘤的诊断及预后标志物的潜力。

Objective To investigate the expression of miR-29 a in osteosarcoma and adjacent non-cancerous tissues,and its correlation with clinicopathologic characteristics. Methods A total of 32 cases of osteosarcoma were collected in the Second People＇s Hospital of Nanyang from March of 2012 to December of 2014. Real-time reverse transcription（ qRT-PCR） was used to detect the expression of miR-29 a in osteosarcoma tissues and adjacent non-cancerous tissues. The correlation of miR-29 a and prognosis with clinical pathologic features were analyzed. Result The expression of miR-29 a was significantly down-regulated in osteosarcoma tissues. The miR-29 a level was negatively correlated with pathologic grading,and it was positively correlated with clinical stage（ all P 0. 05）. Multivariate analyses suggested that clinical stages and miR-29 a expression served as the independent predictors for overall survival respectively. Conclusions miR-29 a may play an important role in the tumorigenesis and tumor progression of osteosarcoma,and it may be a potential prognostic marker and therapeutic target for osteosarcoma.